HES Flare: GSK's Nucala Edges Forward
Marketing Submissions Expected In 2020
GlaxoSmithKline’s interleukin-5 inhibitor, Nucala (mepolizumab), is the first treatment shown to reduce the hypereosinophilic syndrome flare-ups in a 100-patient pivotal study.
